Premium
Novel therapies for Helicobacter pylori infection
Author(s) -
Antone R. Opekun,
H. M. T. El-Zaimaity,
Michael S. Osato,
Mark A. Gilger,
Hoda M. Malaty,
Margaret Terry,
Denis R. Headon,
David Y. Graham
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00435.x
Subject(s) - medicine , helicobacter pylori , lactoferrin , in vivo , adverse effect , antibiotics , spirillaceae , immunology , urea breath test , immune system , antimicrobial , gastroenterology , gastritis , helicobacter pylori infection , microbiology and biotechnology , biology , genetics
Background: Increasing antibiotic resistance has begun to impair our ability to cure Helicobacter pylori infection. Aim: To evaluate orally administered novel therapies for the treatment of H. pylori infection. Methods: Healthy H. pylori infected volunteers received: (a) hyperimmune bovine colostral immune globulins, (b) an oligosaccharide containing an H. pylori adhesion target, Neu5Aca2‐3Galb1–4Glc‐(3′‐sialyllactose), or (c) recombinant human lactoferrin. Outcome was assessed by urea breath test or histological assessment of the number of H. pylori present. Results: None of the novel therapies appeared effective and no adverse events occurred. Conclusion: Although in vitro data appeared promising, in vivo results were disappointing. Higher doses, longer duration of therapy, adjunctive acid suppression, or a combination could possibly yield better results.